Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.

President Trump's unexpected comments about cutting the price of weight-loss drugs, including Novo Nordisk's Ozempic and Wegovy, caused Novo Nordisk (NVO) shares to fall 3.1% and Eli Lilly (LLY) shares to drop 2% on Friday. While a CMS official clarified that negotiations for these GLP-1 drugs have not yet occurred, the remarks signal a broader administration push to lower pharmaceutical costs, following similar agreements with Pfizer and AstraZeneca. The potential for significant price reductions, from over $1,000 to possibly $150, introduces uncertainty for companies heavily invested in the lucrative obesity drug market, despite an unclear timeline for such deals.

Analysis

President Trump's unexpected comments regarding significant price reductions for weight-loss drugs, specifically targeting Novo Nordisk's Ozempic and Wegovy, immediately impacted both companies. Trump suggested prices could drop from over $1,000 to potentially $150, leading to Novo Nordisk (NVO) shares falling 3.1% and Eli Lilly (LLY) shares declining 2% on Friday. This reflects a strongly negative market reaction to the potential erosion of a highly profitable drug category.

While Dr. Mehmet Oz, head of CMS, clarified that negotiations for GLP-1 drugs like Ozempic have not yet commenced, he confirmed such discussions are forthcoming and will continue until the President is satisfied. This initiative aligns with a broader administration push to lower drug prices, evidenced by prior agreements with Pfizer and AstraZeneca. The lack of a clear timeline for these weight-loss drug negotiations introduces significant regulatory uncertainty for the pharmaceutical sector.

The potential for aggressive price cuts poses a substantial threat to the revenue outlook for companies heavily invested in the lucrative weight-loss drug market. Novo Nordisk's stock has reportedly fallen 37% in 2025 (likely 2024 YTD), indicating existing pressure, while Eli Lilly has seen a 3% year-to-date rise. Both companies face considerable headwinds from potential government intervention in pricing, despite the high demand for these medications.

Key Decisions for Investors

• Investors should closely monitor political developments and the progress of drug price negotiations, particularly concerning GLP-1 agonists, given the significant regulatory risk.
• Evaluate the revenue and margin impact on pharmaceutical companies with high exposure to weight-loss drugs, such as NVO and LLY, considering potential price erosion.
• It may be prudent to assess hedging strategies or adjust long-term growth projections for these companies until more clarity emerges on pricing outcomes.